Venous Thromboembolism Management Practice Quiz (56 questions)

All questions and answers

1. A clot formed inside a vein partially obstructs its lumen. What is this condition called?

Pulmonary embolism
Venous thrombosis
Venous stasis
Endothelial injury

Venous thrombosis

Explanation

Venous thrombosis is partial or complete venous obstruction by an intraluminal thrombus formed through coagulation within a vein. Pulmonary embolism involves pulmonary arteries, endothelial injury affects the vessel lining, and stasis means slowed blood flow.

2. A patient has a deep vein clot that has led to obstruction of a pulmonary artery by a traveling thrombus. Which condition pair describes this venous thromboembolic disease?

Venous stasis and deep vein thrombosis
Deep vein thrombosis and pulmonary embolism
Deep vein thrombosis and endothelial injury
Pulmonary embolism and post-thrombotic syndrome

Deep vein thrombosis and pulmonary embolism

Explanation

Venous thromboembolic disease comprises deep vein thrombosis and pulmonary embolism, which can be an immediately life-threatening consequence of DVT. The venous clot is DVT, while PE is obstruction of pulmonary arteries; post-thrombotic syndrome is a possible long-term complication.

3. A clinician evaluating a patient with venous thrombosis organizes the contributing mechanisms into Virchow’s triad. Which set should be included?

Vessel compression, vessel-wall damage, and fibrin formation
Blood-flow stasis, pulmonary obstruction, and altered hemostasis
Blood-flow stasis, platelet adhesion, and red-cell accumulation
Blood-flow stasis, vessel-wall damage, and altered hemostasis

Blood-flow stasis, vessel-wall damage, and altered hemostasis

Explanation

Virchow’s triad consists of slowed blood flow, vessel-wall damage, and altered hemostasis such as hypercoagulability or thrombophilia. Platelet adhesion and fibrin formation are involved in thrombosis but do not replace one of the triad’s three categories.

4. A patient remains on bed rest for several days, slowing venous blood flow. Which effect of this stasis most directly promotes thrombosis?

Compression of the vessel wall
Accumulation of coagulation factors
Depletion of coagulation factors
Alteration of hemostasis independent of blood flow

Accumulation of coagulation factors

Explanation

Venous stasis promotes the accumulation of coagulation factors, which favors clot formation. Compression can be a cause of stasis, while depletion of coagulation factors runs counter to the described mechanism.

5. During clot formation, thrombin acts on circulating fibrinogen. What product does this reaction generate?

Soluble fibrinogen
Red blood cells
Platelets
Insoluble fibrin

Insoluble fibrin

Explanation

Thrombin converts circulating fibrinogen into insoluble fibrin, which then combines with red blood cells and platelets to form a thrombus. Fibrinogen is the substrate, while red blood cells and platelets are components incorporated into the clot.

6. A thrombus is found forming near a venous valve, where blood moves slowly in a rotational pattern. Which composition and local flow condition best fit a typical venous thrombus?

Mainly fibrin and red blood cells, with fast, uniform flow
Mainly fibrin and red blood cells, with low-velocity rotational flow
Mainly platelets and leukocytes, with low-velocity rotational flow
Mainly red blood cells and leukocytes, with fast, uniform flow

Mainly fibrin and red blood cells, with low-velocity rotational flow

Explanation

Venous thrombi consist mainly of fibrin and red blood cells, with variable platelets and leukocytes, and preferentially form at venous valves where slow rotational flow promotes stasis. A platelet-dominant composition or fast, uniform flow does not match these typical venous features.

7. A large pulmonary embolus obstructs pulmonary blood flow. Which immediate hemodynamic change increases the right ventricle’s workload and oxygen demand?

Reduced pulmonary artery pressure and right ventricular afterload
Increased left ventricular afterload and oxygen demand
Increased pulmonary artery pressure and right ventricular afterload
Reduced right ventricular workload and oxygen demand

Increased pulmonary artery pressure and right ventricular afterload

Explanation

Pulmonary vascular obstruction raises pulmonary artery pressure and right ventricular afterload, causing right ventricular dilation, greater workload, and increased oxygen consumption. Reduced afterload reverses the mechanism, while left ventricular afterload and reduced right ventricular demand misassign or invert the effects.

8. A patient has a fibrin-rich, red-cell-rich pulmonary embolus. Where did this type of embolus most likely originate?

The right-sided chambers of the heart
The deep veins of the lower limbs
The pulmonary arteries
The superficial veins of the lower limbs

The deep veins of the lower limbs

Explanation

Most fibrin-rich, red-cell-rich pulmonary emboli originate in the deep veins of the lower limbs. Superficial veins, heart chambers, and pulmonary arteries are not the typical source described for these emboli.

9. Ultrasound identifies a thrombus in a patient’s posterior tibial vein. How should this DVT be classified by location?

Distal DVT, below the popliteal region
Proximal DVT, above the popliteal region
Proximal DVT, within the iliac or caval region
Proximal DVT, within the femoral region

Distal DVT, below the popliteal region

Explanation

The posterior tibial veins lie below the popliteal region, so a thrombus there is distal DVT. Proximal DVT is above the popliteal region, including popliteal, femoral, iliac, and caval veins.

10. A patient has unilateral leg swelling and tenderness, but the findings are nonspecific. What is the appropriate diagnostic conclusion?

The findings raise suspicion, but objective testing is needed to confirm DVT
The findings confirm DVT without any further testing
The findings rule out DVT because they are nonspecific
The findings confirm DVT if the affected limb is compared with the other

The findings raise suspicion, but objective testing is needed to confirm DVT

Explanation

DVT signs are inconsistent and nonspecific; examination should compare both limbs, but clinical findings alone cannot establish the diagnosis, so objective testing is required. Treating the signs as confirmation or considering them a rule-out confuses suspicion with diagnosis.

11. A patient receives one Wells DVT point each for active cancer, calf circumference more than 3 cm larger than the other side, and previous DVT. An alternative diagnosis is at least as likely as DVT. What is the total score?

3 points
5 points
1 point
2 points

1 point

Explanation

The three listed Wells criteria contribute 3 points, and an alternative diagnosis at least as likely as DVT subtracts 2, giving 3−2=13-2=1 point. A total of 3 omits the subtraction; 2 subtracts only one point, while 5 adds rather than subtracts two.

12. A clinician needs to confirm suspected DVT using a test that can be repeated and performed at the bedside. Which test best fits these requirements?

Venous ultrasound with Doppler
Spiral computed tomography of the chest
The Wells DVT score
Homans’ sign assessment

Venous ultrasound with Doppler

Explanation

Venous ultrasound with Doppler is the reference test for confirming DVT and is painless, repeatable, and feasible at the bedside. Spiral chest CT is associated with pulmonary embolism assessment, while the Wells score and Homans’ sign do not objectively confirm DVT.

13. A patient with a markedly swollen, painful leg develops a cold, cyanotic foot with absent pulses. Which clinical form best explains this combination and requires urgent vascular management?

Uncomplicated proximal DVT
Extensive superficial venous thrombosis
Upper-limb DVT
Phlegmasia coerulea dolens

Phlegmasia coerulea dolens

Explanation

Phlegmasia coerulea dolens is a highly obstructive DVT whose severe edema can compress and slow arterial flow, producing a cold, cyanotic limb with absent pulses. Uncomplicated DVT lacks this defining arterial compromise; superficial thrombosis and upper-limb DVT are different clinical forms.

14. A superficial leg-vein thrombus is extensive and lies close to the great saphenous junction. Which assessment of its embolic risk is most accurate?

Risk is absent because the affected vein is superficial
Risk is determined by whether the thrombus is in an upper limb
Risk matches that of DVT regardless of clot extent or location
Risk is lower than with DVT, but extension or proximity to the junction raises concern

Risk is lower than with DVT, but extension or proximity to the junction raises concern

Explanation

Superficial venous thrombosis generally has lower embolic risk than DVT, but extensive clot or proximity to the great saphenous junction increases concern; it may also coexist with or progress to DVT or PE. The superficial location does not eliminate risk, and the risk is not automatically equal to DVT.

15. A pregnant patient has unilateral leg swelling that is difficult to distinguish from common pregnancy symptoms. D-dimer testing is of limited usefulness; which test can confirm suspected DVT without endangering the fetus?

Clinical examination alone
D-dimer testing
Computed tomography venography
Doppler ultrasound

Doppler ultrasound

Explanation

Doppler ultrasound can confirm DVT in pregnancy without danger to the fetus, while D-dimer testing has limited usefulness and symptoms can be difficult to interpret. D-dimer alone is not confirmatory, and the unit identifies Doppler ultrasound as the safe confirmatory approach.

16. A clinician suspects VTE and plans an etiological investigation that may reveal an unrecognized cancer. What should happen to anticoagulant treatment while that investigation is arranged?

Begin anticoagulation without waiting for the investigation
Cancel the investigation once anticoagulation begins
Wait for investigation results before beginning anticoagulation
Fix treatment duration before investigating the cause

Begin anticoagulation without waiting for the investigation

Explanation

The etiological investigation helps determine treatment duration and may uncover conditions such as cancer or antiphospholipid syndrome, but it must not delay anticoagulant treatment. Waiting for results confuses investigation with the immediate need to treat VTE.

17. A patient has undergone surgery and also has a permanent patient-related predisposition to VTE. How should these risks be classified and considered together?

Surgery is permanent, the predisposition is transient, and only one applies
Both are transient events, so their effects do not combine
Surgery is transient, the predisposition is permanent, and their effects can add
Both are permanent patient factors, so surgery does not count

Surgery is transient, the predisposition is permanent, and their effects can add

Explanation

Transient risk factors are provoking events, whereas permanent risk factors are patient-related; multiple factors can coexist and interact additively. Classifying surgery as permanent reverses the distinction, and coexisting risks do not cancel one another.

18. A patient with no prior VTE experiences prolonged travel and later sustains a fracture. Which classification best fits these circumstances as VTE risk factors?

Both are permanent patient-related factors
Travel is transient and the fracture is permanent
Both are transient provoking factors
Travel is permanent and the fracture is transient

Both are transient provoking factors

Explanation

Prolonged travel and fractures are both listed as transient VTE risk factors. Treating either as a permanent patient-related predisposition confuses an event or circumstance with a lasting characteristic of the patient.

19. Which condition is classified as a permanent patient-related risk factor for venous thromboembolism (VTE)?

Acute limb pain
Chronic venous insufficiency
Recent surgery
Anticoagulant treatment

Chronic venous insufficiency

Explanation

Chronic venous insufficiency is a permanent patient-related VTE risk factor. Recent surgery is a transient trigger, acute limb pain is a symptom, and anticoagulant treatment is not a risk factor.

20. A patient with newly diagnosed VTE is awaiting investigations to identify its cause. What should the clinical team do about anticoagulation?

Use the workup to decide whether anticoagulation is needed
Begin anticoagulation without waiting for the workup
Wait for the workup before beginning anticoagulation
Begin anticoagulation only after cancer is confirmed

Begin anticoagulation without waiting for the workup

Explanation

The etiological investigation must not delay anticoagulation, although it helps determine treatment duration and can reveal conditions such as cancer or antiphospholipid syndrome. Waiting for the workup or a cancer diagnosis wrongly makes treatment contingent on those findings.

21. A patient with VTE has both a recent operation and a chronic inflammatory disease. How should these contributors be classified and considered together?

Both are transient triggers, so only the operation contributes
Both are permanent factors, so their effects offset each other
The operation is permanent and the disease transient; their effects are additive
The operation is transient and the disease permanent; their effects are additive

The operation is transient and the disease permanent; their effects are additive

Explanation

A recent operation is a transient triggering event, whereas a chronic inflammatory disease is a permanent patient-related factor; multiple factors may coexist and their interactions are additive. Classifying both as transient or both as permanent ignores this distinction, and coexisting factors do not cancel each other out.

22. After a venous thrombosis, the etiologic investigation identifies no cause. What proportion of cases may have a negative etiologic investigation, requiring continued surveillance?

About 50%
About 10%
About 80%
About 30%

About 30%

Explanation

The etiologic investigation may remain negative in about 30% of venous thrombosis cases, so surveillance is needed. The 80% figure concerns pregnancy-associated events after week 28, 50% overstates the rate, and 10% understates it.

23. A patient’s risk of venous thromboembolism is assessed at age 60 and again at age 70. Based on the age-related pattern, how does the risk change across this decade?

It remains unchanged
It doubles
It triples
It increases by a fixed amount

It doubles

Explanation

After age 40, the risk of venous thromboembolism doubles with each decade, including the decade from 60 to 70. Tripling confuses the size of the increase, a fixed increment is not the stated pattern, and unchanged risk ignores the age-related rise.

24. A person takes a nine-hour flight and remains seated for most of it. How should this exposure be classified in assessing venous thrombosis risk?

Not a travel risk factor unless the flight exceeds twelve hours
A persistent risk factor because sitting exceeds six hours
A transient risk factor only if surgery also occurred
A transient risk factor because sitting exceeds six hours

A transient risk factor because sitting exceeds six hours

Explanation

Prolonged travel with more than six hours seated is a transient risk factor, and identifying such exposures can help limit recurrence. Calling it persistent misclassifies the factor; requiring surgery or a twelve-hour flight adds criteria not stated.

25. A patient with cancer develops thrombosis while a tumor compresses a vein, and laboratory findings indicate increased coagulation. Which mechanisms can account for the thrombosis in this situation?

Hypercoagulability and reduced venous flow resistance
Vascular-wall alteration and increased fibrinolysis
Hypercoagulability and stasis
Reduced coagulation and stasis

Hypercoagulability and stasis

Explanation

Cancer-associated thrombosis can arise through hypercoagulability, vascular-wall alteration, or stasis; the case includes hypercoagulability and tumor-related venous compression causing stasis. Increased fibrinolysis and reduced coagulation are not the mechanisms described, while the final option reverses the effect of compression.

26. A 27-year-old patient is found to have an antithrombin deficiency. Which risk pattern is associated with this deficiency?

A 10- to 50-fold risk, with fewer than half affected before age 30
A 10- to 50-fold risk, with over half affected before age 30
A 10- to 50-fold reduction in risk, with over half affected before age 30
A 2- to 5-fold risk, with over half affected before age 40

A 10- to 50-fold risk, with over half affected before age 30

Explanation

Antithrombin deficiency is associated with a 10- to 50-fold thrombosis risk, and more than half of carriers have a thrombotic episode before age 30. The alternatives alter the multiplier or age-related proportion, or reverse the direction of risk.

27. In a laboratory test, activated protein C is added to a normal plasma sample and to a sample with activated protein C resistance. What happens to the activated partial thromboplastin time (aPTT) in the resistant sample?

It first shortens and then prolongs
It becomes prolonged
It becomes shortened
It remains unchanged

It remains unchanged

Explanation

In activated protein C resistance, adding activated protein C leaves the aPTT unchanged; normal plasma shows prolongation. The other responses incorrectly apply the normal response, reverse the direction, or invent a two-stage change.

28. Which inherited abnormality is the most frequent constitutional thrombophilia associated with thrombosis, and what causes it?

Antithrombin deficiency caused by reduced antithrombin production
Activated protein C resistance caused by the factor V Leiden mutation
Protein C deficiency caused by impaired protein C activation
Protein S deficiency caused by reduced protein S activity

Activated protein C resistance caused by the factor V Leiden mutation

Explanation

Activated protein C resistance is the most frequent constitutional thrombophilia associated with thrombosis and is caused by factor V Leiden, which prevents normal inactivation of factor V by activated protein C. The other choices name distinct inherited deficiencies rather than this mutation.

29. A 42-year-old has a first unprovoked proximal deep-vein thrombosis and a first-degree relative with venous thrombosis. Does this case meet a stated criterion for suggesting a constitutional thrombophilia work-up?

Yes; any unprovoked event meets a stated criterion
No; the event must occur before age 40
No; only recurrent events can meet a stated criterion
Yes; the first-degree family history meets a stated criterion

Yes; the first-degree family history meets a stated criterion

Explanation

A first unprovoked proximal DVT before age 50 with a first-degree family history is a stated indication to suggest testing; this patient meets those criteria at age 42. Any unprovoked event alone is too broad, the age cutoff is 50 rather than 40, and recurrence is not the sole qualifying circumstance.

30. After a deep-vein thrombosis, which set of risks best distinguishes the vital prognosis from the functional prognosis over time?

Short-term vital risk: post-thrombotic syndrome; long-term vital risk: pulmonary embolism or extension; functional risk: recurrence
Short-term vital risk: recurrence; long-term vital risk: post-thrombotic syndrome; functional risk: pulmonary embolism
Short-term vital risk: pulmonary embolism or extension; long-term vital risk: recurrence; functional risk: post-thrombotic syndrome
Short-term vital risk: pulmonary embolism or extension; long-term vital risk: post-thrombotic syndrome; functional risk: recurrence

Short-term vital risk: pulmonary embolism or extension; long-term vital risk: recurrence; functional risk: post-thrombotic syndrome

Explanation

The vital prognosis is threatened in the short term by pulmonary embolism or thrombus extension and in the long term by recurrence; the functional prognosis is linked to post-thrombotic syndrome. The alternatives misassign recurrence, embolism, or post-thrombotic syndrome to the wrong time horizon or type of prognosis.

31. A clinician suspects pulmonary embolism in a patient with symptoms but has not yet estimated clinical probability or ordered imaging. What is the next step in the standard diagnostic sequence?

Reassess the suspicion without estimating probability
Establish the clinical probability of pulmonary embolism
Prescribe a diagnostic examination immediately
Confirm pulmonary embolism from the symptoms alone

Establish the clinical probability of pulmonary embolism

Explanation

The diagnostic process proceeds from suspecting pulmonary embolism to establishing its clinical probability and then prescribing a diagnostic examination. Ordering the examination skips the probability step, while symptoms alone do not confirm the diagnosis.

32. A hemodynamically stable patient is suspected of having pulmonary embolism. What should the clinician do to assess clinical probability?

Proceed directly to diagnostic imaging without formal probability assessment
Use a score designed to determine the anatomical site of embolism
Estimate probability with a validated clinical score such as simplified Wells
Defer probability assessment until the patient becomes unstable

Estimate probability with a validated clinical score such as simplified Wells

Explanation

In the absence of hemodynamic instability, suspected pulmonary embolism calls for a formal clinical-probability estimate using a validated score, such as simplified Wells. Direct imaging skips that assessment, and stability does not eliminate the need to evaluate the suspicion.

33. A patient with suspected pulmonary embolism has active cancer and a heart rate of 108/min, with no other simplified Wells items. How is the clinical probability classified?

Probable, with a score of 2
Improbable, with a score of 1
Improbable, with a score of 2
Probable, with a score of 1

Probable, with a score of 2

Explanation

Active cancer and a heart rate above 100/min each contribute one point, giving a score of 2; a score greater than 1 indicates probable pulmonary embolism. A score of 1 would require omitting one qualifying item, while classifying 2 as improbable reverses the threshold.

34. A ventilation/perfusion scan shows normal lung perfusion in a patient being evaluated for pulmonary embolism. What conclusion follows from this result?

The result is necessarily indeterminate
Pulmonary embolism is confirmed
Pulmonary embolism is excluded
The result cannot inform the embolism assessment

Pulmonary embolism is excluded

Explanation

Normal perfusion on pulmonary ventilation/perfusion scintigraphy excludes pulmonary embolism, even though the test is poorly specific overall. Poor specificity concerns false-positive interpretations; it does not negate the exclusion value of normal perfusion.

35. An echocardiogram in suspected acute pulmonary embolism shows right-chamber dilation without hypertrophy and paradoxical interventricular septal motion. What do these findings represent?

Signs of isolated left-ventricular systolic dysfunction
Direct echocardiographic visualization of pulmonary emboli
Evidence of chronic right-ventricular hypertrophy
Indirect signs of acute cor pulmonale

Indirect signs of acute cor pulmonale

Explanation

Right-chamber dilation without hypertrophy and paradoxical septal motion are among the indirect echocardiographic signs of acute cor pulmonale. These findings indicate right-heart strain rather than directly showing a clot, chronic hypertrophy, or isolated left-ventricular dysfunction.

36. Which set of findings is used to assess the severity of a pulmonary embolism?

Right-ventricular dysfunction, clot size, blood-gas values, and D-dimer level
Hemodynamic instability, clot location, oxygen requirement, and ECG findings
Increased troponins, pulmonary pressure, thrombus source, and anticoagulation response
Hemodynamic instability, right-ventricular dysfunction, increased troponins, and simplified PESI

Hemodynamic instability, right-ventricular dysfunction, increased troponins, and simplified PESI

Explanation

Severity assessment combines hemodynamic instability, right-ventricular dysfunction, myocardial ischemia indicated by increased troponins, and the simplified PESI score. Clot location, clot size, and D-dimer are not substitutes for this specified set.

37. A patient with pulmonary embolism has persistent hypotension that is not due to a recent arrhythmia, hypovolemia, or sepsis. Which severity finding does this meet?

Hemodynamic instability
Intermediate-risk classification
Myocardial ischemia
A simplified PESI score of zero

Hemodynamic instability

Explanation

Persistent hypotension is one of the findings that constitutes hemodynamic instability in pulmonary embolism. Requiring obstructive-shock organ injury confuses this category with one specific form of instability; troponins and PESI are separate assessment elements.

38. After fluid resuscitation, a patient with pulmonary embolism needs vasopressors to maintain systolic pressure at 92 mmHg and has kidney injury from hypoperfusion. How is this finding classified?

Myocardial ischemia
Intermediate-risk pulmonary embolism
Persistent hypotension without shock
Obstructive shock

Obstructive shock

Explanation

Obstructive shock includes the need for vasopressors to maintain systolic pressure at least 90 mmHg despite fluid resuscitation, together with organ injury from hypoperfusion. Right-ventricular dysfunction is a separate severity marker, not the definition of obstructive shock.

39. A patient with pulmonary embolism has no hemodynamic instability, a simplified PESI score of 1, right-ventricular dysfunction, and elevated troponins. Which risk category fits these findings?

Unclassified risk
Low risk
Intermediate risk
High risk

Intermediate risk

Explanation

Intermediate-risk pulmonary embolism has a simplified PESI score of at least 1 together with right-ventricular dysfunction and/or elevated troponins, without the defining hemodynamic instability of high risk. High risk requires hemodynamic instability, while absence of instability alone does not establish low risk.

40. A young adult experiences recurrent deep-vein thrombosis. Which underlying cause should be particularly considered during the investigation?

Malignancy
Thrombophilia
Pulmonary hypertension
Postphlebitic syndrome

Thrombophilia

Explanation

Recurrent deep-vein thrombosis calls for investigation of an underlying cause, with thrombophilia particularly considered in a young person. Malignancy is the association highlighted for older people, while postphlebitic syndrome is a complication.

41. What mechanism underlies postphlebitic syndrome?

Venous valve destruction and venous-wall damage from pre-thrombotic distension
Arterial valve failure and arterial-wall damage from prolonged vasoconstriction
Persistent venous obstruction caused by an untreated active thrombus
Pulmonary artery injury caused by right-ventricular pressure overload

Venous valve destruction and venous-wall damage from pre-thrombotic distension

Explanation

Postphlebitic syndrome is attributed to destruction of venous valves and damage to the venous wall caused by distension before thrombosis. Arterial injury, an active clot, and pulmonary artery pressure overload describe different processes.

42. What is the main purpose of curative anticoagulant treatment for venous thrombosis?

Lower pulmonary arterial pressure and reverse right-ventricular strain
Limit thrombus extension and reduce pulmonary-embolism and early-recurrence risks
Prevent post-thrombotic syndrome and restore venous valve function
Lyse the existing thrombus and immediately reopen the affected vein

Limit thrombus extension and reduce pulmonary-embolism and early-recurrence risks

Explanation

Curative anticoagulation limits venous-thrombus extension and reduces pulmonary-embolism and early-recurrence risks. Preventing venous sequelae is a different treatment goal, while thrombus lysis and reversal of pulmonary strain are not the stated purpose of anticoagulants.

43. A patient receiving initial unfractionated heparin has a body weight of 80 kg. Which starting daily dose and aPTT target are appropriate?

5,000 IU/day, adjusted to an aPTT ratio of 1.5–2.5
40,000 IU/day, adjusted to an aPTT ratio of 2.5–3.0
500 IU/day, adjusted to an aPTT ratio of 1.5–2.5
40,000 IU/day, adjusted to an aPTT ratio of 1.5–2.5

40,000 IU/day, adjusted to an aPTT ratio of 1.5–2.5

Explanation

The initial dose is 500 IU/kg/day, so an 80-kg patient starts at 40,000 IU/day; dosing is adjusted to an aPTT patient-to-control ratio of 1.5–2.5. A fixed 5,000-IU dose ignores weight, while the other choices use an incorrect target or omit the weight factor.

44. An older patient has a creatinine clearance of 27 mL/min. What does the renal-function rule imply for low-molecular-weight heparin?

It is preferred because accumulation risk falls in older patients
It is appropriate if routine anti-Xa monitoring is performed
It is contraindicated because clearance is below 30 mL/min
It is appropriate because clearance remains above 20 mL/min

It is contraindicated because clearance is below 30 mL/min

Explanation

Low-molecular-weight heparins are contraindicated when creatinine clearance is below 30 mL/min, and renal function deserves particular attention in older patients because of accumulation risk. Anti-Xa monitoring does not replace the stated contraindication threshold.

45. A patient begins vitamin K antagonist therapy on the first day of treatment, but the INR has not yet reached 2–3. What should happen to the heparin treatment?

Continue heparin until the INR reaches 2–3
Start the vitamin K antagonist only after heparin ends
Stop heparin once the vitamin K antagonist is started
Continue heparin until the INR rises above 3

Continue heparin until the INR reaches 2–3

Explanation

Vitamin K antagonists are started early, from day 1, while heparin continues until the INR reaches the therapeutic range of 2–3. Stopping heparin at initiation or waiting to start the antagonist reverses the intended overlap.

46. Which treatment distinction best describes anticoagulants compared with fibrinolytics?

Anticoagulants limit migration; fibrinolytics prevent extension without increasing bleeding risk
Anticoagulants limit extension and migration; fibrinolytics lyse the clot and carry greater bleeding risk
Both treatments lyse the clot, but fibrinolytics act more slowly and carry similar bleeding risk
Anticoagulants lyse the clot; fibrinolytics limit extension and migration with lower bleeding risk

Anticoagulants limit extension and migration; fibrinolytics lyse the clot and carry greater bleeding risk

Explanation

Anticoagulants prevent thrombus extension and migration, whereas fibrinolytics lyse the thrombus and carry a much higher bleeding risk. The alternatives reverse the actions or misstate the relative bleeding risk.

47. A patient has pulmonary embolism with shock and no absolute contraindication to fibrinolysis. How should fibrinolysis be used alongside anticoagulation?

Replace anticoagulation with fibrinolysis and end treatment after clot lysis
Use anticoagulation alone and reserve fibrinolysis for stable patients
Add fibrinolysis while shortening anticoagulation to reduce bleeding risk
Add fibrinolysis to anticoagulation without changing its duration or intensity

Add fibrinolysis to anticoagulation without changing its duration or intensity

Explanation

For pulmonary embolism with shock, fibrinolysis should be used unless an absolute contraindication is present, and it supplements rather than changes the duration or intensity of anticoagulation. Using anticoagulation alone or reducing or replacing it does not follow this rule.

48. A clinician is deciding whether a patient should continue anticoagulation after venous thromboembolism. Which paired assessment should guide the duration decision?

VTE-BLEED and HERDOO2 both for bleeding risk
HERDOO2 and VTE-BLEED both for recurrence risk
HERDOO2 for recurrence risk and VTE-BLEED for bleeding risk
Initial clot severity and treatment response, without paired risk assessment

HERDOO2 for recurrence risk and VTE-BLEED for bleeding risk

Explanation

Duration is determined by balancing recurrence risk assessed with HERDOO2 against bleeding risk assessed with VTE-BLEED. Treating both scores as recurrence tools or both as bleeding tools confuses their distinct roles.

49. A patient has a proximal deep-vein thrombosis and no special contraindication to oral anticoagulation. Which approach best reflects the current treatment choice and duration planning?

Use a direct oral anticoagulant and determine duration from thrombotic factors and bleeding and recurrence risks
Use a direct oral anticoagulant for a fixed three-month course regardless of risk factors
Use a direct oral anticoagulant and determine duration from bleeding risk alone
Use low-molecular-weight heparin and determine duration from thrombotic factors and bleeding and recurrence risks

Use a direct oral anticoagulant and determine duration from thrombotic factors and bleeding and recurrence risks

Explanation

Direct oral anticoagulants are the current treatment of choice for proximal deep-vein thrombosis, while duration depends on thrombotic factors and bleeding and recurrence risks. Choosing low-molecular-weight heparin as the default, imposing a fixed course, or ignoring recurrence risk misapplies that approach.

50. A patient has an isolated distal deep-vein thrombosis and active cancer. What treatment duration is indicated by the stated rule?

A shorter course because active cancer is present
Three months, with longer treatment because active cancer is present
A longer course only if the thrombosis becomes proximal
Three months, with no extension because the thrombosis is distal

Three months, with longer treatment because active cancer is present

Explanation

Distal deep-vein thrombosis is treated for three months, with longer treatment when it occurs in the context of active cancer. Keeping the course at three months overlooks the cancer-related extension; requiring proximal extension or shortening treatment also misstates the rule.

51. A patient develops recurrent venous thrombosis despite taking an adequate anticoagulant dose. Which management interpretation is appropriate?

Continue the same dose beyond three months without considering a regimen change
Treat beyond three months and consider a drug switch, dose escalation, or a higher-INR-target vitamin K antagonist
Increase low-molecular-weight heparin only, excluding other treatment strategies
Stop treatment at three months and reassess only if another event occurs

Treat beyond three months and consider a drug switch, dose escalation, or a higher-INR-target vitamin K antagonist

Explanation

Recurrent venous thrombosis requires treatment beyond three months, and recurrence despite an adequate dose may prompt a drug switch, therapeutic-dose escalation, or a vitamin K antagonist with a higher INR target. A fixed stop date, unchanged treatment, or treating dose escalation as the sole option does not capture the stated management choices.

52. One patient has a stable pulmonary embolism, while another has a severe, unstable pulmonary embolism. Which treatment distinction applies?

Use a heparin-to-VKA or DOAC regimen for stable PE; treat severe PE like proximal DVT
Treat both presentations like proximal DVT, without a severity-based distinction
Use the severe-PE regimen for stable PE and reserve the proximal-DVT approach for unstable PE
Treat stable PE like proximal DVT; use a heparin-to-VKA or DOAC regimen for severe or unstable PE

Treat stable PE like proximal DVT; use a heparin-to-VKA or DOAC regimen for severe or unstable PE

Explanation

Stable pulmonary embolism follows the treatment approach for proximal deep-vein thrombosis, whereas severe or unstable PE uses an unfractionated-heparin-to-vitamin-K-antagonist or direct-oral-anticoagulant regimen. Reversing these groups or treating them identically confuses the severity-based distinction.

53. A patient receiving anticoagulation for cancer-associated venous thromboembolism still has active cancer, and the treatment benefit-risk balance remains favorable. What should happen to anticoagulation?

Continue anticoagulation only while symptoms of the thromboembolism persist
Continue anticoagulation while the cancer remains active and the benefit-risk balance remains favorable
Stop anticoagulation after a short fixed course even while the cancer remains active
Continue anticoagulation regardless of cancer activity or the benefit-risk balance

Continue anticoagulation while the cancer remains active and the benefit-risk balance remains favorable

Explanation

For cancer-associated venous thromboembolism, anticoagulation continues while cancer remains active and the treatment benefit-risk balance remains favorable. A fixed stop date ignores ongoing active cancer, while continuation irrespective of the balance or symptom-only criteria misstates the rule.

54. A patient is diagnosed with severe, high-risk pulmonary embolism. Which immediate management setting and intervention are indicated?

A direct oral anticoagulant with routine ward management
Fibrinolysis and management in intensive care or a critical-care unit
Fibrinolysis with routine ward management
Anticoagulation alone and management in intensive care or a critical-care unit

Fibrinolysis and management in intensive care or a critical-care unit

Explanation

Severe, high-risk pulmonary embolism requires fibrinolysis and management in intensive care or a critical-care unit. Anticoagulation alone omits fibrinolysis, and fibrinolysis without critical-care management omits the required level of care.

55. A hospitalized patient has an individually assessed risk of venous thromboembolism. Which preventive plan best reflects the recommended additional measures?

Early mobilization, limb elevation, breathing exercises, elastic compression, and risk-based consideration of prophylactic anticoagulation
Early mobilization, limb elevation, breathing exercises, elastic compression, and routine anticoagulation for every patient
Early mobilization and prophylactic anticoagulation, without compression or breathing exercises
Bed rest, limb elevation, breathing exercises, elastic compression, and risk-based consideration of prophylactic anticoagulation

Early mobilization, limb elevation, breathing exercises, elastic compression, and risk-based consideration of prophylactic anticoagulation

Explanation

Prevention combines early ambulation and mobilization, limb elevation, breathing exercises, and elastic compression; prophylactic anticoagulation may be considered according to individually assessed thrombosis risk. Bed rest is not a preventive measure, omitting compression and breathing exercises leaves out recommended measures, and routine anticoagulation disregards individualized risk assessment.

56. A patient with venous thromboembolism has begun anticoagulation. Which approach to bed rest is appropriate?

Continue bed rest until anticoagulation is completed
Use bed rest as the main treatment alongside anticoagulation
Avoid prescribing bed rest as part of treatment
Delay mobilization until all symptoms have resolved

Avoid prescribing bed rest as part of treatment

Explanation

Bed rest has no role in venous thromboembolism treatment, particularly after anticoagulation has begun. Continuing immobilization because anticoagulation was started confuses treatment with a need for rest, while waiting for treatment completion or symptom resolution adds restrictions unsupported by this principle.

Study with flashcards

Lock in the answers with 94 flashcards on Venous Thromboembolism Management.

What is venous thrombosis?

Partial or complete venous obstruction by an intraluminal thrombus formed when blood coagulates in a vein.

Which conditions comprise venous thromboembolic disease?

Deep vein thrombosis and pulmonary embolism.

What are the three components of Virchow’s triad, according to Rudolph Virchow?

Stasis, vessel-wall damage, and altered hemostasis.

See the flashcards →

Read the study guide

Go over the full study guide for Venous Thromboembolism Management.

Read the study guide →

Related classes

Make your own practice quizzes

Upload your class notes and Revizly writes a practice quiz with explained answers in about a minute.

Quiz maker